282 related articles for article (PubMed ID: 31209428)
1. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients].
Wang SY; Wang S
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
Wang S; Pei L; Hu T; Jia M; Wang S
Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
[TBL] [Abstract][Full Text] [Related]
3. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
Gerber B; von Minckwitz G; Stehle H; Reimer T; Felberbaum R; Maass N; Fischer D; Sommer HL; Conrad B; Ortmann O; Fehm T; Rezai M; Mehta K; Loibl S;
J Clin Oncol; 2011 Jun; 29(17):2334-41. PubMed ID: 21537042
[TBL] [Abstract][Full Text] [Related]
4. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
[TBL] [Abstract][Full Text] [Related]
5. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
[TBL] [Abstract][Full Text] [Related]
6. Ovarian reserve in premenopausal women with breast cancer.
Zong X; Yu Y; Chen W; Zong W; Yang H; Chen X
Breast; 2022 Aug; 64():143-150. PubMed ID: 35691250
[TBL] [Abstract][Full Text] [Related]
7. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
Fréour T; Barrière P; Masson D
Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
[TBL] [Abstract][Full Text] [Related]
8. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
Lee DY; Park YH; Lee JE; Choi D
Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
[TBL] [Abstract][Full Text] [Related]
10. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.
Goldfarb SB; Turan V; Bedoschi G; Taylan E; Abdo N; Cigler T; Bang H; Patil S; Dickler MN; Oktay KH
Breast Cancer Res Treat; 2021 Jan; 185(1):165-173. PubMed ID: 32930927
[TBL] [Abstract][Full Text] [Related]
11. Five-year study assessing the clinical utility of anti-Müllerian hormone measurements in reproductive-age women with cancer.
Palinska-Rudzka KE; Ghobara T; Parsons N; Milner J; Lockwood G; Hartshorne GM
Reprod Biomed Online; 2019 Oct; 39(4):712-720. PubMed ID: 31471141
[TBL] [Abstract][Full Text] [Related]
12. Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer.
Kim SE; Kim WJ; Choi D; Lee DY
Breast Cancer Res Treat; 2023 Apr; 198(2):231-237. PubMed ID: 36781519
[TBL] [Abstract][Full Text] [Related]
13. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Moore HC; Unger JM; Phillips KA; Boyle F; Hitre E; Porter D; Francis PA; Goldstein LJ; Gomez HL; Vallejos CS; Partridge AH; Dakhil SR; Garcia AA; Gralow J; Lombard JM; Forbes JF; Martino S; Barlow WE; Fabian CJ; Minasian L; Meyskens FL; Gelber RD; Hortobagyi GN; Albain KS;
N Engl J Med; 2015 Mar; 372(10):923-32. PubMed ID: 25738668
[TBL] [Abstract][Full Text] [Related]
14. GnRHa for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer.
Zhong Y; Lin Y; Cheng X; Huang X; Zhou Y; Mao F; Wang Y; Guan J; Shen S; Xu Y; Peng L; Li Y; Cao X; Sun Q
J Cancer; 2019; 10(18):4278-4285. PubMed ID: 31413747
[No Abstract] [Full Text] [Related]
15. Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.
Hamy AS; Porcher R; Cuvier C; Giacchetti S; Schlageter MH; Coussieu C; Gronier H; Feugeas JP; Adoui N; Lacorte JM; Poirot C; Habdous M; Espié M
Reprod Biomed Online; 2014 Nov; 29(5):573-80. PubMed ID: 25246112
[TBL] [Abstract][Full Text] [Related]
16. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V
Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324
[TBL] [Abstract][Full Text] [Related]
17. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
Anderson RA; Mansi J; Coleman RE; Adamson DJA; Leonard RCF
Eur J Cancer; 2017 Dec; 87():58-64. PubMed ID: 29117576
[TBL] [Abstract][Full Text] [Related]
18. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer.
Perdrix A; Saint-Ghislain M; Degremont M; David M; Khaznadar Z; Loeb A; Leheurteur M; Di Fiore F; Clatot F
Reprod Biomed Online; 2017 Oct; 35(4):468-474. PubMed ID: 28652099
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study.
Ünal Ç; Ordu Ç; Özmen T; İlgun AS; Çelebi F; Baysal B; Özkurt E; Duymaz T; Erdoğan İyigün Z; Kurt S; Öztürk MA; Pilancı KN; Alço G; Yararbaş K; Kayan Tapan T; Güven DC; Soybir G; Özmen V
Curr Oncol; 2023 Oct; 30(10):9217-9229. PubMed ID: 37887566
[TBL] [Abstract][Full Text] [Related]
20. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.
Anderson RA; Cameron D; Clatot F; Demeestere I; Lambertini M; Nelson SM; Peccatori F
Hum Reprod Update; 2022 May; 28(3):417-434. PubMed ID: 35199161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]